ClinicalTrials.gg
CompletedNCT03194685Updated Dec 24, 2024

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of FF-10101-01 in AML, Adult, sponsored by Fujifilm Pharmaceuticals U.S.A., Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Fujifilm Pharmaceuticals U.S.A., Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
97
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
340th of 1,908
97 · median 35
Started
2017
with 98 others
Phase 1
772 of 2,138
127 open now
Registered
1,374th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 340th largest by enrollment of the 1,908 interventional ones that give a count, is one of 99 that started in 2017, is one of 772 in phase 1, and was the 1,374th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed or refractory acute myeloid leukemia to determine the safety, tolerability, PK and preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD).

Read the detailed description

Subjects will receive FF-10101-01 orally once a day repeated every 28 days =1 cycle Frequent blood draws will be collected to measure pharmacodynamic parameters and pharmacodynamic activity.

Disease assessments, including bone marrow aspirates, will be performed at the beginning of cycles 1-3, and every 3 months thereafter. Subjects who demonstrate objective response or stable disease will be allowed to continue therapy with FF-10101-01 until , observation of unacceptable adverse events, or until the subject is no longer deriving benefit based on the opinion of the investigator.

03

Conditions studied

  • AML, Adult

Keywords

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects who are able and willing to give written

  • Documented primary or secondary AML, as defined by the WHO criteria (2008), by histopathology to previous induction chemotherapy and/or relapsed after achieving remission with a prior chemotherapy and who are not candidates for other available therapy likely to confer clinical benefit.
  • (ECOG) performance status of 0 to 2
  • In the absence of rapidly progressing disease, the interval from prior treatment to time of FF-10101-01 administration should be at least 14 days for cytotoxic agents other than hydroxyurea, at least 5 half-lives for non-cytotoxic agents, and 14 days for monoclonal antibody therapies. Hydroxyurea may be continued for a maximum of 14 days from the start of FF-10101-01 dosing, through Cycle 1 Day 14, with a maximal dose of 5 grams/day
  • Persistent chronic toxicities from prior chemotherapy or surgery must be ≤Grade 2
  • If subject has had a hematopoietic stem cell transplant, subject must be ≥60 days post-transplant with no clinically significant requiring systemic therapy
  • (ALT) and/or aspartate aminotransferase (AST) ≤3 times the and total of ≤1.5x the upper limit of normal. If total bilirubin is equal to or exceeds 1.5x the upper limit of normal, the subject can still be included if direct bilirubin is ≤1.5x the upper limit of normal
  • Calculated of ≥60 mL/min
  • Female subjects of and sexually mature male subjects must agree to use a medically accepted method of other than an oral contraceptive for the duration of the study.

Exclusion Criteria:

  • Subjects diagnosed with acute promyelocytic leukemia
  • Subjects with Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis)
  • Subjects with clinically active CNS leukemia
  • Subjects with major surgery within 28 days prior to the first administration of FF-10101-01
  • Subjects with radiation therapy within 28 days prior to the first administration of FF-10101-01
  • Subjects with active malignant disease requiring therapy other than AML or myelodysplastic syndrome with transformation into AML
  • Subjects with an active uncontrolled infection
  • Subjects with a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the subject's safety as a study subject, or that could interfere with the study objectives
  • Subjects known to have infection, or who have active or C infection as determined by serological testing
  • Subjects with congestive heart failure, (NYHA) Class 3 or 4, or subjects with a past history of congestive heart failure NYHA Class 3 or 4 and in whom echocardiogram or multiple gate acquisition () scan performed within 3 months prior to screening or at screening showed a LVEF \<40%
  • Female subjects who are pregnant or breast feeding
  • Subjects on 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or other drugs known to have muscle toxicity
  • Subjects taking strong inhibitors of will be excluded from the study unless therapeutic substitution is possible
  • Subjects taking strong inducers of CYP3A4 will be excluded from the study unless therapeutic substitution is possible
  • Use of systemic agents within 14 days prior to first dose of FF-10101
  • Subjects taking drugs known to cause Torsades de Pointes will be excluded from the study unless therapeutic substitution is possible
  • Subjects known to have long syndrome
  • Subjects with mean QTcF values following 3 ECGs conducted 5 minutes apart of >470 msec
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Cohort 1: 10 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 2: 20 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 3: 35 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 4: 50 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 5: 75 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 6: 100 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 7: 150 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

  • Experimental
    Cohort 8: 225 mg

    Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01

    Drug: FF-10101-01

Interventions

  • DrugFF-10101-01

    FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.

    Also known as: FF-10101 succinate

06

What researchers measure

Primary outcomes

  1. Phase 1: Frequency of adverse events

    Safety Assessments include frequency of adverse events (AEs) in percentage (%)

    Time frame: 12 months

Secondary outcomes

  1. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Maximum observed concentration (Cmax)

    Maximum observed concentration (Cmax)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  2. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Time to maximum concentration (tmax)

    Time to maximum concentration (tmax)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  3. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Area under the plasma concentration-time curve in the sampled matrix during a 24-hour dosing interval (AUC(τ))

    Area under the plasma concentration-time curve in the sampled matrix during a 24-hour dosing interval (AUC(τ))

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  4. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite -Plasma concentration-time curve (AUC(0-last))

    Area under the plasma concentration-time curve in the sampled matrix from time zero to the last quantifiable concentration, if concentrations are not quantifiable over the entire 24-hour dosing interval (AUC(0-last))

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  5. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Dose normalized AUC(τ) (AUC(τ)/dose)

    Dose normalized AUC(τ) (AUC(τ)/dose)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  6. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Dose normalized Cmax (Cmax/dose)

    Dose normalized Cmax (Cmax/dose)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  7. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Accumulation ratio for AUC

    Accumulation ratio for AUC \[RaccAUC ie, ratio of Day 29/Day 1 of the PK parameter\]

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  8. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Accumulation ratio for Cmax

    Accumulation ratio for Cmax \[RaccCmax ie, ratio of Day 29/Day 1 of the PK parameter\]

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  9. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Oral clearance (CL/F) for FF-10101

    Oral clearance (CL/F) for FF-10101

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  10. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Average concentrations (Cavg)

    Average concentrations (Cavg)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  11. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Minimum observed concentration (Cmin)

    Minimum observed concentration (Cmin)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  12. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Fluctuation index

    Fluctuation index

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  13. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Metabolite (FF-10101M1) to parent (FF-10101) exposure ratios for Cmax

    Metabolite (FF-10101M1) to parent (FF-10101) exposure ratios for Cmax

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  14. Phase 1: Evaluate the Pharmacokinetic profile of FF-10101-01 and its Metabolite - Metabolite (FF-10101M1) to parent (FF-10101) exposure ratios for AUC(τ)

    Metabolite (FF-10101M1) to parent (FF-10101) exposure ratios for AUC(τ)

    Time frame: Cycle 1, Day 1 through Cycle 2, Day 1

  15. Phase 1: Frequency of Serious Adverse Events

    Safety Assessments include frequency of Serious adverse events (SAEs)

    Time frame: 12 Months

  16. Phase 1: Frequency of Dose Limiting Toxicities

    Safety Assessments include frequency of dose-limiting toxicities (DLTs), dose reductions, delays, or withdrawals due to toxicity.

    Time frame: 12 Months

  17. Phase 1: Frequency of adverse events including assessment of Hematology laboratory parameters

    Safety assessments also include assessment of clinical laboratory parameters Hematology

    Time frame: 12 Months

  18. Phase 1: Frequency of adverse events including assessment of serum chemistry laboratory parameters

    Safety assessments also include assessment of clinical laboratory parameters serum chemistry

    Time frame: 12 Months

  19. Phase 1: Frequency of adverse events including assessment of urinalysis laboratory parameters

    Safety assessments also include assessment of clinical laboratory parameters urinalysis

    Time frame: 12 Months

  20. Phase 1: Frequency of Adverse events including assessment of vital signs

    Safety assessments also include assessment of Vital signs (Heart Rate and BP)

    Time frame: 12 Months

  21. Phase 1: Frequency of Adverse events including assessment of vital signs - Heart Rate

    Safety assessments also include assessment of Vital signs Heart Rate

    Time frame: 12 Months

  22. Phase 1: Frequency of Adverse events including assessment of vital signs - Blood Pressure

    Safety assessments also include assessment of Vital signs BP)

    Time frame: 12 Months

  23. Phase 1: Frequency of Adverse events including assessment of 12 lead ECG.

    Safety assessments also include assessment of 12 lead ECG.

    Time frame: 12 Months

  24. Phase 1: Composite complete remission rate (CRc) including CR

    Composite complete remission rate (CRc) which includes CR

    Time frame: 12 Months

  25. Phase 1: Composite complete remission rate (CRc) including CR with incomplete platelet recovery (CRp)

    Composite complete remission rate (CRc) which includes CR with incomplete platelet recovery (CRp)

    Time frame: 12 Months

  26. Phase 1: Composite complete remission rate (CRc) including CR with incomplete neutrophil recovery with or without platelet recovery (CRi))

    Composite complete remission rate (CRc) which includes CR with incomplete neutrophil recovery with or without platelet recovery (CRi))

    Time frame: 12 Months

07

Study locations

7 sites
  • University of California Los Angeles, David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • University Of California, San Francisco School of Medicine
    San Francisco, California 94143, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Johns Hopkins Hospital - Sidney Kimmel Cancer Center
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2021, 50 months.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 50 months is above that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2017
First posted
Jun 21, 2017
StartActual
May 5, 2017
Primary completionActual
Jul 31, 2021
CompletionActual
Jul 31, 2021
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03194685
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Responsible party
Sponsor
First posted
Jun 21, 2017
Start date
May 5, 2017
Primary completion
Jul 31, 2021
Completion
Jul 31, 2021
Last update
Dec 24, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion